Value of trio genome sequencing in early-onset and atypical psychiatric disorders
Official title: A Study of the Value of Trio Genome Sequencing in the Etiological Evaluation of Early-Onset and/or Atypical Psychiatric Disorders Without Intellectual Disability or Congenital Anomalies
Run by Centre Hospitalier Universitaire Dijon · NCT07686653 · Data updated 2026-11-12
This study tests whether sequencing the genomes of a patient and both biological parents can help explain early-onset or unusual psychiatric disorders in people without intellectual disability or congenital anomalies.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 3 Years to 50 Years |
| Sex | All |
| Enrollment | 255 (estimated) |
| Sponsor | Centre Hospitalier Universitaire Dijon Academic / other |
| Locations | 1 site (Dijon) |
| Status | Recruiting |
| Started | September 16, 2026 |
| Main results expected | May 2029 |
| Study ends | May 2029 |
| Registry record updated | September 22, 2026 |
| Trial ID | NCT07686653 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients aged 3–50 with one or more psychiatric disorders, atypical features, and consent from themselves (where applicable) and both biological parents.
✕Probably not a fit
Patients with prior comprehensive genetic testing or lacking parental participation may derive less or no benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study explores the usefulness of trio genome sequencing to identify genetic factors in individuals with early-onset or atypical psychiatric disorders. The approach analyzes the patient and both parents to detect inherited or de novo genetic variations that may contribute to the condition. It does not involve an experimental treatment; instead, it aims to inform diagnostic understanding and care planning. Participants include individuals aged 3 to 50 with at least one psychiatric diagnosis and some degree of atypicality, along with consented parents. The study is conducted at Centre Hospitalier Universitaire Dijon in France and relies on blood samples for genomic analysis.
Why it matters
Potential benefit: If successful, the study could improve diagnostic clarity and guide personalized care for patients with complex psychiatric presentations.
How similar studies have gone: Similar trio-genome approaches have shown promise in other neuropsychiatric contexts, but results in this specific setting are exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Index case with one or more psychiatric disorders confirmed by a psychiatrist and/or child psychiatrist, whose evaluations may be supplemented as needed as part of their care, and who meets at least ONE of the following criteria for atypicality: * Early age of onset * Unusual course of the disorder (polymorphic/fluctuating) * Treatment resistance * Disorder classified as "unspecified" by the DSM-5 with significant functional impact * Index case aged 3 to 50 years, inclusive * Consent signed by the biological parents and by the "index case, if of legal age" * Index case and their parents enrolled in or eligible for a social security program * Sample collection possible from the index case and their two known biological parents Exclusion Criteria: * Genetic testing previously performed (CGH array, targeted gene testing, gene panel, etc.) * Parent(s) and/or the index case subject to a court-ordered protective measure * The index case and his or her parents have a condition that, in the investigator's opinion, would contraindicate the subject's participation in the study * Presence of an intellectual developmental disorder confirmed by a neuropsychological test or strongly suspected clinically in the index case and/or their parents * Index case with a clear syndromic diagnosis * Index case with a psychiatric disorder already covered by a pre-indication under PFMG2025.
Where it's running
-
Chu Dijon Bourgogne
Dijon, France Recruiting
Study contacts
- Study coordinator: Caroline RACINE
- Email: caroline.racine@chu-dijon.fr
- Phone: 03.80.29.53.13
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Genetic testing for AF-triggered cardiomyopathy
We will test whether people who develop heart failure during atrial fibrillation carry specific disease-causing gene variants compared with people who have AF but do not weaken their heart.
-
Genetic factors in Turner syndrome
This project will collect whole-genome samples from people with Turner syndrome and their family members to try to find genes linked to fertility and other health problems.
-
Chorioretinal Imaging and Vascular Biomarkers in Ultra-Trail Runners
This study tests whether noninvasive eye imaging can reveal retinal and choroidal blood vessel changes in ultra-trail runners compared with active controls.
-
Lipid and mitochondrial clues in aortic aneurysm with bicuspid or tricuspid valves
This study tests whether inflammatory and metabolic signatures in myeloid cells and aortic tissue differ between patients with bicuspid versus tricuspid aortic valves who need surgery for ascending aortic aneurysm.
-
Pupillometry to predict postoperative pain after heart surgery
We’re testing whether measuring pupil responses can help predict how much pain a patient will feel after heart surgery once tubes come out and the patient can communicate.
-
BDNF Levels and Atrial Cardiomyopathy in People Having AF Ablation
This study tests whether circulating BDNF levels are linked to atrial cardiomyopathy in adults having their first ablation for persistent atrial fibrillation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.